Literature DB >> 28006062

Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer.

Lisa A Newman1, Azadeh Stark1,2, Dhanajay Chitale2, Margaret Pepe3, Gary Longton3, Maria J Worsham4, S David Nathanson1, Patricia Miller5, Jessica M Bensenhaver1, Erica Proctor1, Monique Swain1, Christos Patriotis6, Paul F Engstrom7.   

Abstract

IMPORTANCE: Compared with white American (WA) women, African American (AA) women have a 2-fold higher incidence of breast cancers that are negative for estrogen receptor, progesterone receptor, and ERBB2 (triple-negative breast cancer [TNBC]). Triple-negative breast cancer, compared with non-TNBC, likely arises from different pathogenetic pathways, and benign breast disease (BBD) predicts future non-TNBC.
OBJECTIVE: To determine whether AA identity remains associated with TNBC for women with a prior diagnosis of BBD. DESIGN, SETTING, AND PARTICIPANTS: This study is a retrospective analysis of data of a cohort of 2588 AA and 3566 WA women aged between 40 and 70 years with a biopsy-proven BBD diagnosis. The data-obtained from the Pathology Information System of Henry Ford Health System (HFHS), an integrated multihospital and multispecialty health care system headquartered in Detroit, Michigan-include specimens of biopsies performed between January 1, 1994, and December 31, 2005. Data analysis was performed from November 1, 2015, to June 15, 2016. MAIN OUTCOMES AND MEASURES: Subsequent breast cancer was stratified on the basis of combinations of hormone receptor and ERBB2 expression.
RESULTS: Case management, follow-up, and outcomes received or obtained by our cohort of 2588 AA and 3566 WA patients were similar, demonstrating that HFHS delivered care equitably. Subsequent breast cancers developed in 103 (4.1%) of AA patients (mean follow-up interval of 6.8 years) and 143 (4.0%) of WA patients (mean follow-up interval of 6.1 years). More than three-quarters of subsequent breast cancers in each subset were ductal carcinoma in situ or stage I. The 10-year probability estimate for developing TNBC was 0.56% (95% CI, 0.32%-1.0%) for AA patients and 0.25% (95% CI, 0.12%-0.53%) for WA patients. Among the 66 AA patients who developed subsequent invasive breast cancer, 16 (24.2%) developed TNBC compared with 7 (7.4%) of the 94 WA patients who developed subsequent invasive breast cancers and had complete biomarker data (P = .01). CONCLUSIONS AND RELEVANCE: This study is the largest analysis to date of TNBC in the context of racial/ethnic identity and BBD as risk factors. The study found that AA identity persisted as a significant risk factor for TNBC. This finding suggests that AA identity is associated with inherent susceptibility for TNBC pathogenetic pathways.

Entities:  

Mesh:

Year:  2017        PMID: 28006062      PMCID: PMC5796807          DOI: 10.1001/jamaoncol.2016.5598

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  38 in total

1.  Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.

Authors:  Amanda I Phipps; Rowan T Chlebowski; Ross Prentice; Anne McTiernan; Jean Wactawski-Wende; Lewis H Kuller; Lucile L Adams-Campbell; Dorothy Lane; Marcia L Stefanick; Mara Vitolins; Geoffrey C Kabat; Thomas E Rohan; Christopher I Li
Journal:  J Natl Cancer Inst       Date:  2011-02-23       Impact factor: 13.506

2.  Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.

Authors:  Mia M Gaudet; Michael F Press; Robert W Haile; Charles F Lynch; Sally L Glaser; Joellen Schildkraut; Marilie D Gammon; W Douglas Thompson; Jonine L Bernstein
Journal:  Breast Cancer Res Treat       Date:  2011-06-11       Impact factor: 4.872

3.  Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

Authors:  Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

4.  Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.

Authors:  C C Nwafor; S O Keshinro
Journal:  Niger J Clin Pract       Date:  2015 Jul-Aug       Impact factor: 0.968

5.  Atypical hyperplasia of the breast--risk assessment and management options.

Authors:  Lynn C Hartmann; Amy C Degnim; Richard J Santen; William D Dupont; Karthik Ghosh
Journal:  N Engl J Med       Date:  2015-01-01       Impact factor: 91.245

6.  Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer.

Authors:  Evelyn Jiagge; Aisha Souleiman Jibril; Dhananjay Chitale; Jessica M Bensenhaver; Baffour Awuah; Mark Hoenerhoff; Ernest Adjei; Mahteme Bekele; Engida Abebe; S David Nathanson; Kofi Gyan; Barbara Salem; Joseph Oppong; Francis Aitpillah; Ishmael Kyei; Ernest Osei Bonsu; Erica Proctor; Sofia D Merajver; Max Wicha; Azadeh Stark; Lisa A Newman
Journal:  Ann Surg Oncol       Date:  2016-07-28       Impact factor: 5.344

7.  A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.

Authors:  Julie R Palmer; Christine B Ambrosone; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2013-12-17       Impact factor: 2.506

8.  Risk factors for breast cancer from benign breast disease in a diverse population.

Authors:  Maria J Worsham; Usha Raju; Mei Lu; Alissa Kapke; Alyssa Botttrell; Jingfang Cheng; Varsha Shah; Adnan Savera; Sandra R Wolman
Journal:  Breast Cancer Res Treat       Date:  2008-10-04       Impact factor: 4.872

Review 9.  Breast cancer disparities: high-risk breast cancer and African ancestry.

Authors:  Lisa A Newman
Journal:  Surg Oncol Clin N Am       Date:  2014-07       Impact factor: 3.495

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

View more
  4 in total

1.  Pan-cancer clinical and molecular analysis of racial disparities.

Authors:  Olivia D Lara; Ying Wang; Amma Asare; Tao Xu; Hua-Sheng Chiu; Yuexin Liu; Wei Hu; Pavel Sumazin; Shitanshu Uppal; Lin Zhang; J Alejandro Rauh-Hain; Anil K Sood
Journal:  Cancer       Date:  2019-11-15       Impact factor: 6.860

2.  Differences in somatic TP53 mutation type in breast tumors by race and receptor status.

Authors:  Nijole C Pollock; Johnny R Ramroop; Heather Hampel; Melissa A Troester; Kathleen Conway; Jennifer J Hu; Jo L Freudenheim; Olufunmilayo I Olopade; Dezheng Huo; Elad Ziv; Susan L Neuhausen; Patrick Stevens; Joseph Paul McElroy; Amanda Ewart Toland
Journal:  Breast Cancer Res Treat       Date:  2022-03-14       Impact factor: 4.872

3.  The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial.

Authors:  Marie E Wood; Heshan Liu; Elizabeth Storrick; David Zahrieh; H Carisa Le-Petross; Sin-Ho Jung; Patricia Zekan; M Margaret Kemeny; Jayne R Charlamb; Lili X Wang; Gary W Unzeitig; Candace S Johnson; Judy E Garber; James R Marshall; Isabelle Bedrosian
Journal:  Cancer Prev Res (Phila)       Date:  2021-04-13

Review 4.  Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer.

Authors:  Margarite D Matossian; Alexandra A Giardina; Maryl K Wright; Steven Elliott; Michelle M Loch; Khoa Nguyen; Arnold H Zea; Frank H Lau; Krzysztof Moroz; Adam I Riker; Steven D Jones; Elizabeth C Martin; Bruce A Bunnell; Lucio Miele; Bridgette M Collins-Burow; Matthew E Burow
Journal:  Womens Health Rep (New Rochelle)       Date:  2020-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.